Related Experiment Video
Updated: Aug 6, 2026

A Microfluidic Chip for ICPMS Sample Introduction
Published on: March 5, 2015
An integrated system of micromixers and microfluidic concentration gradient chips assisted drug screening over large
Huanhuan Shi1,2, Weizheng Xu3, Ziwen Cheng3
1Department of Neurology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330052, People's Republic of China. shihuanhuancsu@126.com.
Abstract:
There is an unmet need for a versatile platform that enables flexible multi-drug combination screening with a wide concentration range and automated operation. Accordingly, an automated multi-drug combination screening platform (ISMMCGs) integrating elliptical baffle micromixers (EBMixers) and three types of microfluidic concentration gradient (MCG) chips was developed. The EBMixer achieves > 90% mixing efficiency within a 40 mm channel (Re = 0-70), ensuring rapid uniform mixing. The MCG chips (linear, two-fold, ten-fold dilution), designed via the equivalent circuit method, spanning a four-order-of-magnitude concentration gradient (10⁻⁴-1). Automated switching via a micro-solenoid valve array enables "rough/fine/precise" screening. Validation with sodium fluorescein confirms gradient reliability; Screening experiments of vancomycin against MRSA demonstrate that this system can narrow the OD600-determined apparent MIC range down to 0.78-1.01 µg/mL, verifying the application potential of this platform in rapid screening of antimicrobial concentration ranges; and tigecycline-colistin sulfate combination screening for MDR-AB verifies the platform's flexibility for concentration-dependent combinatorial testing. This integrated platform addresses the limitations of traditional methods by balancing wide concentration coverage, multi-drug flexibility, and automation. It provides a refined, cost-effective tool for drug screening, facilitating the development of personalized treatment regimens and accelerating drug discovery processes, with broad applications in antimicrobial resistance research and pharmaceutical development.

